Quanta to Present at the 40th Annual Dialysis Conference
4 January 2020: Quanta Dialysis Technologies Ltd, a British med-tech company that has developed SC+, a personal haemodialysis (HD) system, today announces that the Company will be presenting at the 40th Annual Dialysis Conference (ADC), which runs from 8 to 11 February 2020, at the Kansas City Convention Center, Missouri, USA.
In addition, Quanta announces it has filed a 510(k) submission with the FDA for SC+, with a follow-up study planned to then extend use to Home HD. John E. Milad, Chief Executive Officer of Quanta, said: “We are delighted to be working with leading US Home HD experts on this
important study that will help us to bring SC+ to American patients and healthcare professionals. SC+ has been designed to make home dialysis accessible to more patients, supporting the objectives of the Advancing American Kidney Health Initiative.”
Dr. Paul Komenda, Chief Medical Officer, will provide an update on SC+, explaining how it will enable choice, efficiency and empowerment to both patients and physicians in the “Home Dialysis Machines” session on Monday, 10 February at 2:00pm.
The presentation will be followed by a device demonstration at 4:15pm.
Full details of the session are as follows
Session: Home Dialysis Machines
Date: Monday 10 February
Time: 2:00pm
Quanta will also be presenting a poster at ADC, reporting on the annual therapy cost of dialysis when using SC+ in Canada. The results demonstrate the feasibility of cost-saving when using a small and easy-to-use haemodialysis system like SC+ on an every-other day treatment regimen.
Full details of the poster presentation are as follows
Title: Annual Therapy Cost of Dialysis with the Quanta SC+ Personal Haemodialysis System
Location: Home Dialysis
First Presentation: Sunday 9 February between 1:00pm – 2:00pm
Second Presentation: Monday 10 February between 1:00pm – 2:00pm
If you would like to arrange a meeting with John E. Milad, Chief Executive Officer, or Paul Komenda, Chief Medical Officer, at the conference, please contact enquiries@quantadt.com.